What's New

 

Updated 4/22/08

Go straight to news links

This page is designed to bring you some of the latest information on Multiple Sclerosis and related health topics. We post a series of headline "links" to the original articles and leave it to you to choose which you will view.

~ Please note that some of the links require you to become members of the newsgroup in order to view the article. ~

To read any article, click on the headline and go to the original source page.

 

~ April 2008 ~

Early Treatment With COPAXONE(R) Significantly Delayed Progression To Clinically Definite Multiple Sclerosis

Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of Rituxan In Primary-Progressive Multiple Sclerosis

Potential MS Therapy for Myelin Repair Advanced By Minnesota Partnership

Xanthus’ Symadex Reverses Disease in Preclinical Mouse Models of Multiple Sclerosis

Oral Drug Reduces Disease Activity In Multiple Sclerosis

Co-Payments Soar for Drugs With High Prices

Termination shouldn't be the answer to a disability

MS Workplace - the first-of-its-kind online initiative that provides MS-specific career advice, workplace tips, and job postings for the MS community

Potential New Target For Multiple Sclerosis Therapy

Unraveling How A Drug Helps Patients With Multiple Sclerosis

Loss Of Mobility Found To Impact Quality Of Life And Emotional And Financial Health Of Most People Living With MS

New Tool To Study The Link Between Body Temperature And Severity Of MS Symptoms

Mouse Nerve Cells Protected From Damage By New Drug

Multiple Sclerosis: Prognosis Better Than Expected

 

~ March 2008 ~

UW tries worm eggs to help MS patients

Study Refutes Prior Claim that Blood Test Can Predict Course of MS

Researchers Report Success Promoting Myelin Repair

New Hope for SSDI Applicants

New SSDI Guidebook Available To Individuals With Mutiple Sclerosis

Biogen issues warning on Tysabri

New Clinical Evidence Shows Treatment Breakthrough For Foot Drop In Chronic Stroke And Traumatic Brain Injury Survivors

Merck Serono Launches New Formulation Of Interferon Beta-1a

Stanford Researchers Find Protein Targets For Potential Treatment Of Multiple Sclerosis

Promising Experimental MS Drug Offers New Window On Disease

 

~ February 2008 ~

An Oldie Vies for Nutrient of the Decade

I'm Ill, but Who Really Needs to Know?

Heartbreaking Work - Caregiving in America

Stanford researchers ID therapy targets for MS treatment

Rituxan may be called new drug for MS

New MS Drug Target Shows Promise

Lack of sunshine can be hazardous

Multiple Sclerosis Response To Treatment May Vary Depending On Patients' Genes

Smoking Marijuana Impairs Cognitive Function In MS Patients

Dutch firm eyes cannabis pill in 5 years

Treatment of Cognitive Impairment in MS: Is the Use of Acetylcholinesterase Inhibitors a Viable Option?

Unexpected multiple sclerosis: follow-up of 30 patients with MRI and clinical conversion profile.

Machine May Help MS Patients With Mobility

Multiple Sclerosis Linked to Genes

New therapeutic target for the treatment of multiple sclerosis

Multiple Sclerosis Response To Treatment May Vary Depending On Patients' Genes

BioMS Medical's Pivotal International Multiple Sclerosis Trial for SPMS Receives Positive Review From Data Safety Monitoring Board

 

 

~ January 2008 ~

Genetic Differences May Help Explain Response to Multiple Sclerosis Treatment

Study finds why some benefit from MS drug

New Way To Block Destructive Rush Of Immune Cells Found

Subcutaneous interferon-beta-1a : new formulation

Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis

Efficacy of paroxetine in treating major depressive disorder in persons with MS

Allergy, family history of autoimmune diseases, and the risk of multiple sclerosis

Alexithymia (inability to express one's feelings) in multiple sclerosis: relationship with fatigue and depression

Apitope MS Vaccine Shows Promise

Hospital puts a spring in the step of patients

BioMS Medical's Pivotal International Multiple Sclerosis Trial Receives Positive Review From Data Safety Monitoring Board

MS Society (UK) Welcomes Information On Sativex

New drugs and hopes for an MS vaccine

The reliability of the MSFC and its components

Worsening of symptoms is associated with lower physical activity levels in individuals with MS

 

~ December 2007 ~

Gene Plays Protective Role In MS

Drug Combo With Antibiotic May Slow MS Progression

Combining antibiotic, interferon may benefit MS patients: study

AVANIR Enrolls First Patient in Confirmatory Phase III Trial of ZenviaT in PBA

Who gets Multiple Sclerosis?

Tech Transfer Initiative Aims To Speed Development Of MS Treatments

Hepatitis B Vaccine Is Not Linked To Multiple Sclerosis In Childhood

Early Treatment With COPAXONE Demonstrated Robust Protection Against Progression To Clinically Definite Multiple Sclerosis In The PreCISe Study

 

~ November 2007 ~

Approval for Phase IIB Trial of AIMSPRO

Stem cells give hope on MS and arthritis

Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b

Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier

Further Evidence To Link EBV Virus Infection With MS

Initiation of Enrollment in Pivotal Phase III Clinical Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis

New Biotech Company, Allozyne raises $30 million to develop new MS treatment

Stem Cell Transplantation for Aggressive Multiple Sclerosis

Cognitive Dysfunction in Benign MS

Minocycline Has Harmful Effect on Patients With Motor Neuron Disease

Large Trial Of Oral Antibiotic Minocycline Set To Begin In People At Risk For MS

Bayer dropping bid to market higher-dose MS treatment Betaferon

Accessible Technology Can Help People with Multiple Sclerosis, but Too Few Use It

Study Showed Patients Using Copaxone Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)

Antibody Leads To Repair Of Myelin Sheath in MS

 

For archived news stories, go to What's New II